Miguel Ayala
Family · San Ramon, CANPI 1538446448
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $84,140 of the $123,660 with a category attached, or 68.0%. AbbVie accounts for 79.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $43,877 and has fallen 53.6% since, to $20,338 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 563 payments — averaging $219.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$98K
- Gilead$24K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$987
- Lilly USA, LLC$163
- Insulet Corporation$112
- Novo Nordisk$80
What the payments were for
- Consulting fees$6,8746%
- Speaking & faculty fees$84,14068%
- Travel & lodging$21,70418%
- Food & beverage$10,9309%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 321 | $98,477 |
| Gilead | 181 | $23,841 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 49 | $987 |
| Lilly USA, LLC | 4 | $163 |
| Insulet Corporation | 4 | $112 |
| Novo Nordisk | 4 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$123,660 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 187 | $289,700 |
| MavyretGlecaprevir/Pibrentasvir | 23 | $284,609 |
| RezdiffraResmetirom | 24 | $106,650 |
| JardianceEmpagliflozin | 53 | $78,346 |
| XifaxanRifaximin | 17 | $49,412 |
| MounjaroTirzepatide | 25 | $32,242 |
| OzempicSemaglutide | 30 | $29,067 |
| TrulicityDulaglutide | 21 | $21,681 |
| RybelsusSemaglutide | 14 | $21,593 |
| Tenofovir Disoproxil Fumarate | 29 | $18,853 |
| JanuviaSitagliptin Phosphate | 11 | $13,629 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,943 |
| Ursodiol | 24 | $3,449 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $3,134 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $2,636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $23,841 | $289,700187 claims |
| AbbVieMavyret | $98,477 | $284,60923 claims |
| Lilly USA, LLCMounjaro, Trulicity | $163 | $53,92346 claims |
| Novo NordiskOzempic, Rybelsus | $80 | $50,65944 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $987 | $49,41217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in San Ramon
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.